Sell Alert: Sagimet Biosciences (SGMT)

Less than six weeks ago, on Friday, September 6, we recommended buying shares of Sagimet Biosciences (Nasdaq: SGMT).  Since we published our report, Sagimet’s management has appeared at several institutional-investor conferences and has also released a fuller data set confirming its blockbuster Phase II clinical trial results for the company’s lead drug candidate denifanstat.   Yesterday,

Sell Alert: Vanda Pharmaceuticals (VNDA)

Over my decades in investing, I’ve learned the hard way that recognizing mistakes as quickly as possible, and then acting decisively to fix them – if need be, by trimming or exiting a position – is one of the cardinal attributes that separate professionals from amateurs. And so you can count on me to raise